African-Americans tend to be diagnosed at a later stage of Alzheimer’s disease—limiting the effectiveness of treatments that depend upon early intervention.
African-Americans are seriously underrepresented in current clinical trials of potential treatments for Alzheimer’s disease—particularly in trials conducted by drug companies —even though evidence of genetic differences and response to drugs varies significantly by race and ethnicity.
Reproduced with the permission of the Alzheimer's Association. Copyright 2004 Alzheimer’s Association, www.alz.org, 800.272.3900
